DOSE RANGING PHASE 2 STUDY OF BOTOX® (ONABOTULINUMTOXINA) IN IDIOPATHIC OAB: BENEFIT RISK ASSESSMENT

被引：2

作者：

Chapple, C. R. ^{[1
]}

Dmochowski, R. ^{[2
]}

Nitti, V. ^{[3
]}

Chancellor, M. ^{[4
]}

Everaert, K. ^{[5
]}

Thompson, C. R. ^{[6
]}

Daniell, G. ^{[7
]}

Zhou, J. ^{[8
]}

Haag-Molkenteller, C. ^{[7
]}

机构：

[1] Royal Hallamshire Hosp, Dept Urol, Sheffield S10 2JF, S Yorkshire, England

[2] Vanderbilt Univ, Dept Urol, Nashville, TN USA

[3] NYU, Sch Med, Dept Urol, New York, NY 10003 USA

[4] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA

[5] Ghent Univ Hosp, Dept Urol, Ghent, Belgium

[6] Allergan Ltd, Urol Therapeut Area, Marlow, Bucks, England

[7] Allergan Pharmaceut Inc, Urol Therapeut Area, Irvine, CA USA

[8] Allergan Pharmaceut Inc, Dept Biostat, Irvine, CA USA

来源：

关键词：

D O I：

10.1016/S1569-9056(10)60098-X

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：62 / 62

页数：1